How Staging Systems Describe a Mesothelioma Diagnosis
Doctors use staging systems to track and measure the progression of cancer. Combined with diagnostic procedures such as biopsies and radiological imaging, cancer staging allows physicians to finalize a prognosis and cancer treatment plan.
Imaging tests such as CT-scan, MRI or PET measure the size and distribution of tumors as well as identify lymph node involvement or metastatic disease. Staging systems translate these results into a number system that oncologists use to give cancer a “stage.”
There are four stages of pleural mesothelioma: stages 1 and 2 are early in the disease process, and stages 3 and 4 involve widespread tissue involvement or multiple tumors.
These stages differ slightly depending on the staging system. Historically, there have been three staging systems used for pleural mesothelioma, but TNM is the commonly accepted method.
- TNM: Tumor Node Metastasis is the most-used staging system for malignant pleural mesothelioma and also provides the most information. A number after each letter details the presence and extent of tumor mass throughout the body.
- Butchart: The oldest mesothelioma staging system, the Butchart method, is based on the location of the primary tumor and has mostly fallen out of use. This system does not account for tumor size or overall tumor mass in the body.
- Brigham: Dr. David Sugarbaker, a pioneer of mesothelioma treatment, developed this system at Brigham and Women’s Hospital. The Brigham method emphasizes the feasibility of surgery through each stage of progression.
There are no formal staging systems for pericardial mesothelioma or testicular mesothelioma.
Free Mesothelioma Nutrition Guide
Eating right and balancing your diet while undergoing mesothelioma treatment can help ease your symptoms.Get Free Recipes and Tips
TNM Staging System
This is the most widely used system for pleural mesothelioma. It is also called the iMiG Staging System after the International Mesothelioma Interest Group, which is the organization that developed it.
The abbreviation TNM signifies three different parts of a mesothelioma diagnosis. Doctors add a number after each letter to describe how far cancer has advanced. A modified version of this system loosely defines the stages of peritoneal mesothelioma as well.
The TNM staging system is a three-part description that defines cancer by:
- T: The size and location of tumor tissue (ranges from T0 to T4).
- N: The presence of cancer in nearby lymph nodes (ranges from N0 to N2).
- M: Describes if tumors have spread (or metastasized) to distant body sites (M0 or M1).
These values then determine the stage of mesothelioma, from 1 to 4. Stages 1 and 3 also have substages 1A, 1B, 3A and 3B.
- Stage 1A: T1 N0 M0
- In the earliest stage of mesothelioma, T1 indicates tumor involvement on one side of the chest with possible participation in deeper tissues of the pleura. Tumors may also be present in the pleura that lines the breathing muscle, called the diaphragm, or the area between the lungs, known as the mediastinum.
- Stage 1B: T2 N0 M0 or T3 N0 M0
- T2 tumors involve deeper tissue in the pleura plus invasion of the diaphragm muscle or inner lung tissue.
- If the primary tumor is T3, it may still be resectable, but has advanced into deeper fat tissues of one of the following:
- The first layer of the chest wall
- A single place within deeper layers of the chest wall
- The fatty tissue between the lungs
- The outer layer of the heart lining (pericardium)
- Larger and more advanced tumors may cause respiratory and cardiac issues, such as pleural effusion or irregular heart rate. Tumors involving the inner lung tissue often cause symptoms similar to lung cancer.
- Stage 2: T1-2 N1 M0
- Beginning at stage 2, N1 indicates lymph node involvement on the same side of the primary tumor’s origin.
- Stage 3A: T3 N1 M0
- The first type of stage 3 mesothelioma has advanced into the chest wall, heart lining or the mediastinum. It has also entered a lymph node on the same side.
- Stage 3B: T1-3 N2 M0 or T4, Any N, M0
- N2 describes cancer in lymph nodes opposite the origin site. T4 tumors are unresectable and have extended into at least one of the following:
- More than one place in deeper layers of the chest wall, such as the muscle or ribs
- Through the breathing muscle and into the abdominal lining (peritoneum)
- Any organ between the lungs (esophagus, trachea, thymus and blood vessels)
- The spine
- The other side of the chest
- Through the heart lining or into the heart
- Stage 4: Any T, Any N, M1
- The TNM method notes metastasis as being either present (M1) or absent (M0). Pleural mesothelioma is stage 4 if distant metastasis has occurred, regardless of T or N value. Metastasis sites typically include the liver, kidneys, bone, abdominal lining, inner lung or pleural lining on the other lung.
TNM for Peritoneal Mesothelioma
In 2011, the Peritoneal Surface Oncology Group International proposed a staging system for peritoneal mesothelioma. To create the staging system, the group gathered data on peritoneal patients who had surgery with heated chemotherapy.
This system has not been formally adopted, but many doctors use it to define three peritoneal mesothelioma stages.
A fourth stage has not been created yet because this system is based on patients who qualified for surgery. Researchers did not have enough data to define a fourth stage because only early-stage patients qualify for surgery.
In the future, a fourth stage will likely be defined. Until then, doctors generally define the fourth stage as when the cancer spreads to distant parts of the body.
T1 N0 M0: Presence of tumors is minimal and contained within the abdominal lining (peritoneum).
T2-T3 N0 M0: Tumors are moderate and contained in the abdominal lining.
T4 N0-N1 M0-M1: Presence of tumors is extensive (T4) and may or may not have spread to lymph nodes (N0-N1) or beyond the abdominal lining (M0-M1).
T1-T4 N1 M0-M1: Tumors may range from minimal to extensive (T1-T4). The cancer has spread to lymph nodes (N1) and may or may not have spread outside the abdominal lining (M0-M1).
T1-T4 N0-N1 M1: Presence of tumors may range from minimal to extensive (T1-T4). The cancer may or may not have spread to lymph nodes (N0-N1), but has spread outside the abdominal lining (M1).
Early Staging Systems
Before the adoption of the TNM system, oncologists used two other methods for staging pleural mesothelioma. In 1998, Dr. David Sugarbaker developed the Brigham staging system, which focused on surgery and whether a patient is eligible at different stages of progression.
Dr. Eric Butchart devised the first mesothelioma staging system in 1976, but the technique is not commonly used and is limited in detail.
Brigham Staging System
The Brigham staging system was created by Dr. David Sugarbaker at the Brigham and Women’s Hospital in Boston. With this system, doctors look at organs, tissues and other parts of the body to learn how far pleural mesothelioma has spread.
This system is primarily designed to determine whether a patient qualifies for surgery. In the first two stages, tumors are small and easier to remove. In stage 3 and stage 4, the cancer has grown and spread and it is not easy to operate.
Tumors are only in the lining of the lungs, and cancer has not spread to the lymph nodes. Surgery is an option.
Tumors are within the lining of the lungs. Lymph nodes near the tumors are cancerous. Surgery is an option.
Inoperable tumors are in the lining of the lungs and have spread into one or more of the following:
- The area between the lungs
- The chest wall
- The breathing muscle
- Distant lymph nodes
Cancer has spread to distant parts of the body. Surgery is not an option.
Butchart Staging System
Dr. Eric Butchart created this system in 1976 to make sure patients got the right treatment.
Now retired, Butchart was a cardiothoracic surgeon at the University Hospital of Wales in the United Kingdom when he developed this staging system.
Butchart realized aggressive treatment worked better for patients with small tumors that had not spread far. He based his staging system on this fact, which helped doctors decide what treatments would work best for each patient.
This system is outdated and no longer used, but it helped other doctors develop the staging systems we use today.
The cancer affects the pleura on only one side of the chest and may have spread to the heart lining and diaphragm.
Cancer has spread to the chest wall and may affect both sides of the pleura. It may have spread to the esophagus, heart or lymph nodes of the chest.
Cancer has spread to the breathing muscle or abdominal lining (peritoneum). Mesothelioma cells have also traveled through the lymphatic system to lymph nodes outside the chest.
The cancer has spread through the bloodstream to distant parts of the body. Tumors may now be present in the bones, liver, brain or other organs.
Staging System Updates
As researchers gather more knowledge on the progression of malignant pleural mesothelioma, the criteria that define each stage may change again. An evolving staging system equips doctors with the knowledge to offer treatment plans tailored to distinct stages.
The most recent change was the eighth edition of the TNM system for malignant pleural mesothelioma published by the American Joint Committee on Cancer in 2018.
Prominent changes included collapsing T1a and T1b into just T1, refining N components by eliminating the N3 category, and changing stage 4 to be concerned only with the presence of metastasis.
Over time, mesothelioma staging systems will continue to offer more defined diagnoses, allowing physicians to treat patients with more significant effect and higher chances of survival.
6 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
Tan, W.W. (2019, November 1). Malignant Pleural Mesothelioma Staging.
Retrieved from: https://emedicine.medscape.com/article/1999306-overview
American Cancer Society. (2018, November 16). Malignant Mesothelioma Stages.
Retrieved from: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/staging.html
Berzenji, L, Van Schil, P.E. & Carp, L. (2018, October). The eighth TNM classification for malignant pleural mesothelioma.
Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204412/
Bonomi, M. et al. (2017). Clinical Staging of Malignant Pleural Mesothelioma: Current Perspectives. Lung Cancer: Targets and Therapy, 8, 127-139.
Retrieved from: https://pubmed.ncbi.nlm.nih.gov/28860886/
Rice, D. et al. (2016, December). The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.
Retrieved from: https://pubmed.ncbi.nlm.nih.gov/27687964/
- Yan, T.D. et al. (2011, May 1). A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of a Multi-Institutional Database. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/21509762/
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified September 18, 2020